Diflunisal

CHEMBL898 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
250.2 g/mol
LogP
4.4
Phase
4

An NSAID derived from salicylic acid, used to treat mild to moderate pain including that from osteoarthritis. It is metabolized differently from aspirin and does not produce the same level of antiplatelet effects. Its half-life is longer than aspirin, allowing twice-daily dosing.

Peso Molecular

250,2000 g/mol

LogP

4,40

TPSA

57,50 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Mecanismo de Ação

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O

InChI

InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)

Molecular Formula

C13H8F2O3

HBD / HBA

2 / 5

Ligações Rotacionáveis

2

Átomos Pesados

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An NSAID derived from salicylic acid, used to treat mild to moderate pain including that from osteoarthritis. It is metabolized differently from aspirin and does not produce the same level of antiplatelet effects. Its half-life is longer than aspirin, allowing twice-daily dosing.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Diflunisal is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL898. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3059. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.